Drugs / V160
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials · 1 met primary | ||||||
| Phase 1 | NCT03840174 | Mar → Nov 2019 | cytomegalovirus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01986010 | Nov 2013 → Apr 2016 | cytomegalovirus infection | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT03486834 | Apr 2018 → Oct 2020 | cytomegalovirus infection | Merck Sharp & Dohme LLC | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V160 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03840174 ↗ |
| Modality | Vaccine | “V160, a conditionally replication-defective virus, is an investigational vaccine under evaluation for prevention of congenital CMV.” PMID 33031517 ↗ Jun 2021 |
| Route | Intramuscular | “V160 administered as a 0.75 mL intramuscular injection” NCT01986010 ↗ |